Cargando…

Cell Therapies in Bladder Cancer Management

Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockad...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Lucia, Paramio, Jesús M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999326/
https://www.ncbi.nlm.nih.gov/pubmed/33802203
http://dx.doi.org/10.3390/ijms22062818
_version_ 1783670756713955328
author Morales, Lucia
Paramio, Jesús M.
author_facet Morales, Lucia
Paramio, Jesús M.
author_sort Morales, Lucia
collection PubMed
description Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockade inhibitors as a therapeutic option for BC represents an unprecedented advance in BC management. However, although some patients show durable responses, the fraction of patients showing benefit is still limited. Notwithstanding, cell-based therapies, initially developed for the management of hematological cancers by infusing immune or trained immune cells or after the engineering of chimeric antigen receptor (CAR) expressing cells, are promising tools to control, or even cure, solid tumors. In this review, we summarize recent cell-based immunotherapy studies, with a special focus on BC.
format Online
Article
Text
id pubmed-7999326
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79993262021-03-28 Cell Therapies in Bladder Cancer Management Morales, Lucia Paramio, Jesús M. Int J Mol Sci Review Currently, bladder cancer (BC) represents a challenging problem in the field of Oncology. The high incidence, prevalence, and progression of BC have led to the exploration of new avenues in its management, in particular in advanced metastatic stages. The recent inclusion of immune checkpoint blockade inhibitors as a therapeutic option for BC represents an unprecedented advance in BC management. However, although some patients show durable responses, the fraction of patients showing benefit is still limited. Notwithstanding, cell-based therapies, initially developed for the management of hematological cancers by infusing immune or trained immune cells or after the engineering of chimeric antigen receptor (CAR) expressing cells, are promising tools to control, or even cure, solid tumors. In this review, we summarize recent cell-based immunotherapy studies, with a special focus on BC. MDPI 2021-03-10 /pmc/articles/PMC7999326/ /pubmed/33802203 http://dx.doi.org/10.3390/ijms22062818 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Morales, Lucia
Paramio, Jesús M.
Cell Therapies in Bladder Cancer Management
title Cell Therapies in Bladder Cancer Management
title_full Cell Therapies in Bladder Cancer Management
title_fullStr Cell Therapies in Bladder Cancer Management
title_full_unstemmed Cell Therapies in Bladder Cancer Management
title_short Cell Therapies in Bladder Cancer Management
title_sort cell therapies in bladder cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999326/
https://www.ncbi.nlm.nih.gov/pubmed/33802203
http://dx.doi.org/10.3390/ijms22062818
work_keys_str_mv AT moraleslucia celltherapiesinbladdercancermanagement
AT paramiojesusm celltherapiesinbladdercancermanagement